MOG Antibody–Associated Disease and Thymic Hyperplasia
From the National Multiple Sclerosis Society Case Conference Proceedings
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received September 28, 2022
- Accepted in final form October 26, 2022
- First Published December 14, 2022.
Author Disclosures
- Brigitte Hurtubise, MD,
- Elliot M. Frohman, MD, PhD,
- Steven Galetta, MD,
- Laura J. Balcer, MD,
- Teresa C. Frohman, MPAS, PA-C,
- Robert P. Lisak, MD,
- Scott D. Newsome, DO,
- Jennifer S. Graves, MD, PhD, MAS,
- Scott S. Zamvil, MD, PhD and
- Lilyana Amezcua, MD, MS
- Brigitte Hurtubise, MD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Elliot M. Frohman, MD, PhD,
None
NONE
Genzyme-Speaker feesNovartis-Speaker feesAlexion-Speaker feesJanssen-Speaker fees
J of Neurology-Editorial BoardFrontiers in Neurology-Editorial BoardJ of the Neurological Sciences-Editorial BoardNeuroimmunology Reports-Editorial Board
NONE
1. Up To Date: i). Internuclear ophthalmoparesisii). Multiple Sclerosis: Symptom management2) Cambridge University PressOptical Coherence Tomography in Neurological Diseases
NONE
NONE
GenzymeNovartisAlexionJanssen
NONE
NONE
NONE
NONE
NONE
National MS Society
NONE
NONE
NONE
NONE
NONE
NONE
- Steven Galetta, MD,
None
NONE
z
(1) Neurology, Editorial Board;(2) Journal of Neuro-ophthalmology, Editorial Board
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Laura J. Balcer, MD,
Editor in Chief, Journal of Neuro-Ophthalmology, receive payments from the North American Neuro-Ophthalmology Society
NONE
None
Journal of Neuro-Ophthalmology, Editor-in-Chief, 2019-present
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIH
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Teresa C. Frohman, MPAS, PA-C,
spouse:Genzyme, Alexion, Novartis, JANSSEN- speaking and consulting
NONE
Spouse: Genzyme, Alexion, Novartis
self and spouse:Editor Neurology ReportsContributor: Up To DateNMSS Fellows Webinar Case Conference Proceedings
NONE
Self: Up-To-DateSpouse: Up-To-Date
NONE
Spouse: Genzyme, Alexion, Novartis, Janssen
Spouse:Genzyme, Alexion, Novartis, Janssen
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Robert P. Lisak, MD,
1) Advisory Board Commercial: Argenx, Mallinckrodt, Takeda, Alivant, ANI, MedDay, Horizon 2) Advisory Board non-profit: National Multiple Sclerosis Society, Michigan Chapter, Clinical Advisory Committee; Myasthenia GravisFoundation of America, Clinical Advisory Committee;Guillain-Barre Syndrome/CIDP Foundation, International,Global Medical Advisory Commmittee
NONE
None
Section Editor for Neuroimmunology, ClinicalNeuropharmacology, 2005-present; Editorial Board,Immunology Research, 1986-2021; Neuroimmunology Reports 2020-present
NONE
International Neurology: A Clinical Approach, Blackwell,Oxford, 2009; 2017 (2nd edition)Neuroimmunology, Oxford University Press, 2019
NONE
1)GLG Consulting; Insight Consulting; Alpha SitesConsulting; Argenx; Clearview Consulting, Guidepoint Consulting; Jupiter Consulting; Dedham, Triangle Insights, Horizon Pharmaceuticals, ALI, Alivar,Takeda, COUR (Data Safety Monitoring Board) and ACTHar Gel, Takeda consulting on autoimmune neurologic disorders, Janssen consulting on S1P receptor modulators
NONE
Health Advisory Committee; National MultipleSclerosis Society, Michigan Chapter, Board of Governors;Research Grants Committee and Centers of ExcellenceCommittee of the Medical Advisory Committee of theGBS/CIDP Foundation, International; Grants Committee ofthe Myasthenia Gravis Foundation of America ended-2020
NONE
Alexion; Genentech, Novartis,Medimmune; Chugai, UCB/Ra Pharmaceuticals, Argenx, Takeda paid to Wayne State University for my participation in clinical trialsMedDay as Chair of Adjudication Committee for study ofbiotin in progressive forms of MS
NINDS; 1R21NS118227-01; PI; 7/15/2020-06/30/2023
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Scott D. Newsome, DO,
Biogen Idec, scientific advisory boardGenentech, scientific advisory boardEMD Serono, scientific advisory boardBristol Myers Squibb, scientific advisory boardGreenwich Biosciences, scientific advisory boardNovartis, scientific advisory boardHorizon Therapeutics, scientific advisory boardmedDay Pharmaceuticals, clinical adjudication committee member for a clinical trial
NONE
None
NONE
NONE
NONE
NONE
Autobahn
NONE
study lead PI for a Roche clinical trial
NONE
Biogen Idec; research support payed directly to my institution and not relevant to the submitted manuscriptGenentech; research support payed directly to my institution and not relevant to the submitted manuscriptRoche; research support payed directly to my institution and not relevant to the submitted manuscript
NONE
NONE
National Multiple Sclerosis SocietyDepartment of DefensePatient Centered Outcomes Research InstituteThe Stiff Person Syndrome Research Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Jennifer S. Graves, MD, PhD, MAS,
Novartis, Genentech, Bayer
NONE
None
Assistant editor for Neurology 2020-2021Associate editor for ACTN 2019-2022
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1) Octave2) Biogen3) EMD Serono4) Sanofi
NONE
NONE
1) National MS Society
NONE
NONE
NONE
NONE
NONE
NONE
- Scott S. Zamvil, MD, PhD and
Dr. Zamvil has received honoraria for serving on Data Safety Monitoring Boards for MS trials conducted by Opexa, BioMS, Teva Pharmaceuticals, Inc. and Eli Lilly and Co. Foundation.
NONE
(1) Biogen - Speaker honoraria and advisory board meetings(2) Teva - Speaker honoraria and advisory board meetings(3) Alexion - Speaker honoraria and advisory board meetings(4) Novartis - Speaker honoraria and advisory board meetings(5) Horizon - Speaker honoraria and advisory board meetings
(1) Neurology, Neuroimmunology and Neuroinflammation,Deputy Editor, 2014-present
"Aquaporin-4 peptides and methods for using same"(SF2010-074; USF-461PRV (pending). The applicationdescribes the discovery of aquaporin-4 T cell determinantsin neuromyelitis optica patients and the use forantigen-specific tolerance.
NONE
NONE
SSZ has served as a consultant to Biogen Idec, Teva Neuroscience, EMD-Serono, Genzyme, Novartis, Genentech/Roche, Horizon and Alexion.
Advanced Health Media, 2009-presentBiogen, 2009-presentAlexion, 2019-presentViela Bio, 2020Horizon, 2021-present
NONE
NONE
(1) Biogen - speaker and advisory board meetings(2) Teva - speaker and advisory board meetings(3) Genentech - advisory board meeting(4) Novartis - advisory board meetings(5) Genzyme - advisory board meetings(6) Alexion - advisory board meeting(7) Horizon - advisory board meetings
NIH RO1 AI131624-O1A1NIH R21 NS10815990-01
NMSS RG 1701-26628NMSS RG 1801-29861
Alexander M. and June L. Maisin Foundation, PI
NONE
NONE
NONE
NONE
NONE
NONE
- Lilyana Amezcua, MD, MS
1) Genentech, 2) EMD Serono
NONE
Genentech, Biogen Idec, EMD Serono, Sanofi/Genzyme
NONE
NONE
NONE
NONE
1)Biogen Idec, 2)Novartis, 3)Genentech, 4)EMD Serono,
NONE
NONE
NONE
Genentech, Sanofi
1) NIH NINDS 1R01NS096212‐01 , Co-PI, 5 years 2) NIN NINDS 1R01NS123398-01, PI, 5 years
NONE
1) National Multiple Sclerosis Society NMSS 2)Race to Erase MS3) Bristol Myers Squibb Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (B.H., L.A.), University of Southern California (USC), Keck School of Medicine; Distinguished Senior Fellows (Sabbatical) Neuroimmunology Laboratory of Professor Lawrence Steinman (E.M.F., T.C.F.), Stanford University School of Medicine, Palo Alto, CA; Departments of Neurology (S.G., L.J.B.), Population Health (L.J.B.) and Ophthalmology (L.J.B., S.G.), New York University Grossman School of Medicine; Department of Neurology (R.P.L.), Wayne State University, Detroit MI; Department of Neurology (S.D.N.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Neurosciences (J.S.G.), University of California, San Diego; and Department of Neurology and Program in Immunology (S.S.Z.), University of California, San Francisco.
- Correspondence
Dr. Zamvil zamvil{at}ucsf.neuroimmunol.org
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. David E. Vaillancourt and Dr. Shannon Y. Chiu
► Watch
Related Articles
- No related articles found.